List of Excipients in Branded Drug ACETADOTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cumberland Pharmaceuticals Inc	ACETADOTE	acetylcysteine	66220-207	NITROGEN
Cumberland Pharmaceuticals Inc	ACETADOTE	acetylcysteine	66220-207	SODIUM HYDROXIDE
Cumberland Pharmaceuticals Inc	ACETADOTE	acetylcysteine	66220-207	WATER

ACETADOTE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 6, 2026

Acetadote is Cumberland Pharmaceuticals' intravenous acetylcysteine product for reducing the risk of hepatic injury after acetaminophen overdose. Its formulation uses a narrow excipient system centered on sodium hydroxide for pH adjustment and sterile water for injection. The commercial opportunity is therefore less dependent on novel excipient innovation than on ready-to-use presentation, stability, administration safety, procurement economics, and differentiated hospital packaging.

Acetadote's core drug substance is genericized acetylcysteine. The main competitive risks are approved generic injections, hospital substitution, and alternative presentations rather than biosimilar competition. The strongest product opportunities are premixed infusion bags, pharmacy-efficient dosing formats, reduced preparation error, and supply reliability.

What is Acetadote and how is it administered?

Acetadote contains acetylcysteine injection at a concentration of 200 mg/mL. It is administered intravenously using a three-bag or two-bag regimen based on patient weight and clinical protocol. The FDA-approved indication is reduction of the risk of hepatic injury in patients with acute acetaminophen overdose, including patients whose ingestion time is unknown or who present late after ingestion (FDA, 2023a).

Acetadote product profile

Attribute	Acetadote profile
Active ingredient	Acetylcysteine
Route	Intravenous
Strength	200 mg/mL
Product type	Sterile injectable solution
Indication	Acetaminophen overdose
NDA holder	Cumberland Pharmaceuticals, Inc.
FDA approval	2004
Preservative status	No preservative identified in the FDA labeling
Primary excipients	Sodium hydroxide and sterile water for injection
Administration	Dilution into compatible intravenous solutions before infusion
Primary users	Emergency departments, intensive-care units, poison-control-directed hospital services

The FDA label states that Acetadote is a clear, colorless solution. The formulation uses sodium hydroxide to adjust pH. The label instructs dilution before administration and identifies compatibility constraints relevant to hospital preparation (FDA, 2023a).

What excipients are used in Acetadote?

Acetadote uses a minimal excipient platform. The labeled inactive ingredients are sodium hydroxide and sterile water for injection. Sodium hydroxide is used to adjust the solution to the required pH; it is not intended to provide a therapeutic function.

Excipient composition

Excipient	Function	Commercial relevance
Sodium hydroxide	pH adjustment and control of acetylcysteine solution chemistry	Supports stability and product quality
Sterile water for injection	Vehicle	Enables parenteral administration
Preservatives	None identified in the label	Reduces preservative-related compatibility and tolerability concerns

A minimal formulation is commercially useful for an emergency injectable. It limits the number of materials that must be qualified, reduces potential incompatibilities, and simplifies quality control. The tradeoff is that the product has limited formulation-based differentiation from generic acetylcysteine injections.

Why is pH control important for acetylcysteine injection?

Acetylcysteine contains a reactive sulfhydryl group and is susceptible to oxidation and chemical degradation. pH control, oxygen exposure, container closure, storage temperature, and dilution conditions are central to product stability.

The formulation must maintain an acceptable pH while avoiding unnecessary excipient complexity. Strong alkaline adjustment can improve solubility and control the final pH, but excessive alkalinity can create local tolerability, degradation, or compatibility concerns. A commercial formulation must therefore balance pH, color change, impurity formation, container compatibility, and in-use stability.

The FDA labeling warns that diluted acetylcysteine solutions can develop a light pink or purple color without loss of potency. The label also identifies the need to use diluted solutions within specified time periods and under defined storage conditions (FDA, 2023a).

Formulation-development priorities

For an Acetadote competitor or line extension, the main technical priorities are:

1. Control of oxidation and degradation products.
2. Low particulate burden in a high-concentration sterile injectable.
3. Container closure compatibility.
4. Consistent pH after dilution.
5. Robustness during hospital preparation.
6. Stability in commercially useful premixed containers.
7. Protection against dosing and dilution errors.

Potential formulation tools include oxygen-reduced headspace, improved container closures, light protection, optimized fill volumes, and validated overwrap systems. Any additional antioxidant, chelator, buffer, or surfactant would require a clear benefit because each new excipient introduces regulatory, compatibility, extractables, leachables, and parenteral safety considerations.

What formulations are protected by Acetadote patents?

The historic Acetadote patent estate was directed principally to acetylcysteine compositions and methods of use rather than to a broad platform of complex excipient technology. Public FDA Orange Book records and patent disclosures should be reviewed for the specific current listing status, but Acetadote does not present the same active patent barrier associated with newer small-molecule products or biologics.

Cumberland's commercial protection historically relied on a combination of FDA approval, brand recognition, hospital contracts, manufacturing controls, and product-specific regulatory positioning. The key commercial protection for a generic competitor is therefore regulatory approval and supply execution.

Patent and exclusivity assessment

Protection category	Acetadote position
Active ingredient patent	Acetylcysteine is an old, well-established active ingredient
Core product patent	Historic composition and method claims have largely aged beyond their commercial life
Formulation patents	Limited differentiation from the simple aqueous formulation
Method-of-use patents	Acetaminophen-overdose treatment is established and vulnerable to generic substitution
New chemical entity exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Regulatory exclusivity	The original approval exclusivity period has expired
Current market barrier	ANDA approval, sterile manufacturing, supply reliability, and contracting

A competitor should not assume that the absence of a major active patent eliminates all launch risk. Patent scope, Orange Book listings, FDA approval history, manufacturing know-how, and potential product-specific litigation must be checked before launch. The principal obstacle is usually sterile injectable execution rather than active-ingredient ownership.

When did Acetadote lose exclusivity?

Acetadote's original FDA approval was granted in 2004. Any original regulatory exclusivity associated with that approval has expired. Acetylcysteine itself has been marketed for decades, and the active ingredient does not create a new-chemical-entity barrier.

The practical market question is whether a proposed generic can obtain approval under the applicable ANDA pathway and meet injectable manufacturing requirements. A generic applicant may file a Paragraph IV certification if it challenges a listed patent, or a Paragraph III certification if it accepts a later patent expiration. Where no blocking listed patent remains, an applicant may proceed through the standard ANDA process subject to FDA approval and other regulatory requirements.

What is the Orange Book status of Acetadote?

Acetadote is associated with FDA-approved prescription drug listing information and historical patent records in the Orange Book. The Orange Book remains the controlling source for current listed patents, exclusivity, therapeutic equivalence, and reference-product information (FDA, 2024).

A commercial diligence review should distinguish among:

• The reference listed drug status.
• Current and expired patent listings.
• Any pediatric exclusivity.
• Therapeutic equivalence codes for approved generic acetylcysteine injections.
• Product-specific labeling differences.
• Whether a proposed generic is eligible for immediate approval or faces a certification-based delay.

Because Orange Book entries can change, current litigation or launch analysis should rely on the latest FDA publication rather than historic patent summaries.

Which companies are challenging Acetadote?

The competitive field consists primarily of manufacturers of generic acetylcysteine injection and suppliers of hospital compounding or premixed intravenous products. Acetadote does not face a biosimilar pathway because acetylcysteine is a chemically defined small molecule, not a biologic.

Generic competition can enter through:

• 200 mg/mL single-dose vials.
• Multi-dose or single-dose presentations where permitted.
• Premixed infusion bags.
• Institutional supply contracts.
• Emergency-department purchasing channels.
• Compounding pharmacy or outsourced sterile-compounding channels, subject to applicable law.

The most relevant competitors are manufacturers with approved sterile injectable capacity, established hospital distribution, and reliable access to vials, stoppers, filling lines, and qualified contract manufacturing.

What commercial opportunities exist in Acetadote excipient strategy?

The largest opportunity is not a new excipient. It is a lower-risk administration system.

Ready-to-use infusion products

Acetadote requires dilution before intravenous administration. A premixed presentation could reduce pharmacy labor, shorten preparation time, and lower the probability of concentration or volume errors. Potential formats include weight-banded bags corresponding to common dosing protocols.

Commercial advantages include:

• Reduced manipulation in emergency settings.
• Lower exposure to acetylcysteine odor during preparation.
• Less pharmacy compounding labor.
• Fewer dilution calculations.
• More predictable final concentration.
• Better suitability for emergency-department stocking.

The principal development risks are stability after dilution, container compatibility, shipping conditions, microbial control, and the need to support multiple weight-based regimens.

Low-volume concentrated systems

A concentrated vial can reduce storage volume and transport weight. This model favors hospital pharmacies with established compounding infrastructure. It is less attractive where hospitals prioritize ready-to-administer products or have limited pharmacy staffing.

Premixed bags with optimized container systems

An improved container could use a low-oxygen headspace, a compatible multilayer bag, and protective secondary packaging. These measures may extend shelf life or improve resistance to discoloration without adding pharmacologically active excipients.

The strongest intellectual-property position would likely come from a specific combination of formulation concentration, container, oxygen-control process, storage condition, and in-use stability. Broad claims to acetylcysteine alone would be difficult to defend against established prior art.

Packaging and dosing aids

Commercial differentiation can also come from:

• Weight-based dosing labels.
• Color-coded sequence identifiers.
• Barcode-enabled administration.
• Unit-of-use emergency kits.
• Tamper-evident closures.
• Integrated dilution instructions.
• Electronic medication-administration compatibility.

These features may be protectable through design, packaging, or process rights, but they generally provide weaker barriers than a validated formulation or container-closure system.

What manufacturing and IP barriers affect generic launch?

Sterile injectable manufacturing is the central barrier. Acetylcysteine injection requires control of bioburden, endotoxin, particulates, fill accuracy, container closure integrity, and aseptic processing. Manufacturing must also control oxidation and color change during filling and storage.

Key barriers

Barrier	Impact on launch
Aseptic filling capacity	Can create long development and validation timelines
Sterile container supply	Vial, stopper, and bag shortages can delay launch
Stability program	Required to support shelf life and post-dilution use
Extractables and leachables	Important for bags, tubing, and closures
Particulate control	Critical for injectable approval
Supply continuity	Hospital contracts favor dependable suppliers
Labeling and dosing	Errors can create clinical and product liability exposure
API quality	Oxidation and impurity control affect release testing

A generic manufacturer with an established injectable platform can have a meaningful advantage over an oral-drug company entering the market for the first time.

What generic launch scenarios exist for Acetadote?

The most likely launch scenarios are:

Single-dose vial substitution

This is the lowest-complexity commercial strategy. It competes mainly on price, availability, and contract terms. Differentiation is limited.

Premium generic with improved packaging

A manufacturer can preserve some price premium through better labeling, unit-dose packaging, barcoding, or reduced preparation burden.

Ready-to-administer product

A premixed product has the strongest potential to change purchasing criteria. Hospitals may accept a higher price if the product lowers pharmacy workload and medication-error risk.

Dual-source hospital contracting

Hospitals and group purchasing organizations may prefer a branded-plus-generic supply model to protect continuity. A reliable second source can obtain share even without the lowest price.

How does Acetadote compare with oral acetylcysteine?

Factor	Acetadote	Oral acetylcysteine
Route	Intravenous	Oral
Emergency use	Rapid hospital administration	Limited by vomiting, aspiration risk, and tolerance
Excipient burden	Minimal aqueous injectable formulation	More formulation flexibility
Main commercial barrier	Sterile manufacturing	Taste, tolerability, and dosage form
Patent opportunity	Container, stability, premix, dosing system	Taste masking, modified release, dosage form
Biosimilar risk	None	None
Substitution	Institutional and protocol-driven	More dependent on patient tolerance and clinical setting

The intravenous product commands value because it is integrated into emergency treatment workflows. The commercial advantage is operational, not based on a complex excipient platform.

What is the revenue exposure for Acetadote?

Revenue exposure is concentrated in hospital and emergency-care purchasing. Demand is linked to acetaminophen overdose incidence, poison-control protocols, emergency-department utilization, and institutional formulary status. The product is not a chronic therapy and does not have recurring outpatient prescription volume comparable with maintenance drugs.

The main revenue risks are:

• Generic price erosion.
• Hospital conversion to lower-cost alternatives.
• Premixed competing products.
• Group purchasing organization negotiations.
• Supply interruptions.
• Reduced brand preference after patent expiry.
• Low clinical differentiation between approved acetylcysteine injections.

The main revenue opportunities are premium-priced convenience, dependable supply, and products that reduce preparation requirements.

How strong is the Acetadote patent estate?

The patent estate is weak as a long-term exclusionary barrier because the active ingredient is old, the formulation is relatively simple, and the original regulatory exclusivity has expired. Commercial strength comes from execution factors:

1. FDA-approved labeling and reference-product status.
2. Hospital purchasing relationships.
3. Sterile manufacturing capability.
4. Supply reliability.
5. Packaging and workflow integration.
6. Potentially differentiated ready-to-use presentations.

A new entrant seeking defensible protection should focus on a specific formulation-container-process combination supported by comparative stability and operational data. A standalone claim to acetylcysteine injection or routine pH adjustment is unlikely to provide durable protection against established prior art.

Key Takeaways

• Acetadote is a 200 mg/mL intravenous acetylcysteine solution for acetaminophen overdose.
• The labeled excipient strategy is minimal: sodium hydroxide for pH adjustment and sterile water for injection.
• The principal formulation risks are oxidation, discoloration, pH control, container compatibility, and post-dilution stability.
• Original regulatory exclusivity has expired, and biosimilar competition does not apply.
• Generic competition is driven by sterile manufacturing, FDA approval, contracting, and supply reliability.
• The strongest commercial opportunity is a ready-to-use or pharmacy-efficient presentation.
• A defensible new patent position would likely require a defined formulation, container, oxygen-control process, or stability profile.
• Orange Book, FDA approval, and litigation records must be checked for current product-specific status before a launch or licensing decision.

FAQs

Is Acetadote preservative-free?

The FDA labeling identifies sodium hydroxide and sterile water for injection as inactive ingredients and does not identify a preservative. Acetadote is supplied as a sterile injectable product intended for dilution and intravenous administration.

Can acetylcysteine injection be sold as a premixed bag?

A premixed bag would require a product-specific regulatory strategy supported by stability, container-closure, sterility, particulate, compatibility, and labeling data. It may be developed as a new presentation or as a differentiated product depending on the applicable FDA pathway.

Does Acetadote have biosimilar competition?

No. Acetylcysteine is a chemically defined small molecule. Competitors generally use generic-drug pathways rather than the FDA biosimilar pathway.

What is the most valuable excipient innovation for acetylcysteine injection?

The most valuable innovation is likely an excipient-minimal stability system combined with an optimized container and premixed presentation. Adding multiple excipients without a measurable stability or usability benefit would increase regulatory and manufacturing complexity.

Can a new acetylcysteine formulation receive patent protection?

Potentially, but protection would need to rest on a specific, non-obvious formulation or delivery configuration. Examples include a defined concentration and pH range, a container system with improved stability, an oxygen-control process, or a premixed product with validated extended in-use stability.

References

1. U.S. Food and Drug Administration. (2023a). Acetadote (acetylcysteine) injection prescribing information. Cumberland Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2023b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. DailyMed. (2024). Acetadote: Acetylcysteine injection labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/